BRIEF-Huyabio International Announces Hbi-8000 And Nivolumab Combination Reduces The Risk Of Disease Progression By 27% In Patients With Advanced Melanoma In Phase 3 Trial

1

Oct 22 (Reuters) – * HUYABIO INTERNATIONAL ANNOUNCES HBI-8000 AND NIVOLUMAB COMBINATION REDUCES THE RISK OF DISEASE PROGRESSION BY 27% IN PATIENTS WITH ADVANCED MELANOMA IN PHASE 3 TRIAL Source text:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)